2001 CTOS Annual Meeting Posters— Surgery

INTRAPERITONEAL CHEMOTHERAPY (IPC) AFTER COMPLETE RESECTION OF PERITONEAL SARCOMATOSIS (PS): RESULTS OF A MONOCENTRIC RANDOMIZED STUDY
Bonvalot Sylvie,  Calvacanti Andrea,   Elias Dominique,  Terrier Philippe,  Vanel Daniel,  Lepechoux Cecile,   Le Cesne Axel
Institut Gustave Roussy

METHODS: patients (pts) with complete resection of PS were randomized between adjonction of IPC or not. IPC consisted of Doxorubicin, 0.1 mg/kg and Cisplatine, 15 mg/m² every day for 5 consecutive days.

RESULTS: thirty-eight consecutive pts have been enroled in the study, 19 in each group (IPC-, IPC+) with a M/F sex ratio of 14/24. Median age was 58 (39 to 72) and 48 yrs (31 to 71) in IPC- and IPC+ group respectively. Ratio of retroperitoneal (RPS) and visceral (VS) sarcomas were 9/10 and 6/13 in IPC- and IPC+ group respectively. Histoprognostic grade and median number of organs resected during surgery were similar in both groups. Sugarbaker score of sarcomatosis were 13 (3, 27) and 13,7 (2, 20) in IPC- and IPC+ respectively. There was no toxic deaths and morbidity was similar in both groups (4 pts in each group). Median time of hospitalization was 22 days (range 11 to 39) for IPC- and 24 days (range 15 to 42) for IPC+. The median follow-up is 36 months .The median local relapse-free survival and overall survival were identical in both groups, 12.5 and 18 months respectively with no difference between RPS and VS.

CONCLUSION: Addition of IPC did not modify outcome of pts after complete resection of RPS and VS. OS and DFS of this study are similar to those observed in phase II studies combining IPC with hypertermia. An optimal surgery of PS remains the only pronostic factor for survival.